Neuroscience 2012-12-13

Bryostatin-1 promotes long-term potentiation via activation of PKCα and PKCε in the hippocampus.

H Kim, S H Han, H Y Quan, Y-J Jung, J An, P Kang, J-B Park, B-J Yoon, G H Seol, S S Min

文献索引:Neuroscience 226 , 348-55, (2012)

全文:HTML全文

摘要

Activation of protein kinase C (PKC) by bryostatin-1 affects various functions of the central nervous system. We explored whether bryostatin-1 influenced synaptic plasticity via a process involving PKC. Our purpose was to examine whether bryostatin-1 affected the induction of hippocampal long-term potentiation (LTP) in Schaffer-collateral fibers (CA1 fibers) of the hippocampus, and/or influenced the intracellular Ca(2+) level of hippocampal neurons. We also determined the PKC isoforms involved in these processes. We found that bryostatin-1 strongly facilitated LTP induction, in a dose-dependent manner, upon single-theta burst stimulation (TBS). Further, intracellular Ca(2+) levels also increased with increasing concentration of bryostatin-1. The facilitative effects of bryostatin-1 in terms of LTP induction and enhancement of intracellular Ca(2+) levels were blocked by specific inhibitors of PKCα and PKCε, but not of PKCδ. Our results suggest that bryostatin-1 is involved in neuronal functioning and facilitates induction of LTP via activation of PKCα and/or PKCε.Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.


相关化合物

  • Bryostatin 1

相关文献:

Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine

2010-01-01

[Cytokine 52(3) , 238-44, (2010)]

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

2011-01-01

[Leuk. Res. 35(1) , 87-94, (2011)]

Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.

2011-01-01

[Cell. Immunol. 271(2) , 392-400, (2011)]

HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.

2011-01-01

[Clin. Dev. Immunol. 2011 , 780839, (2011)]

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

2012-04-01

[Invest. New Drugs 30(2) , 723-8, (2012)]

更多文献...